Is MedAvail Holdings, Inc. overvalued or undervalued?

As of 15 October 2023, MedAvail Holdings, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 12.5, a price-to-sales (P/S) ratio of 1.2, and a return on equity (ROE) of 15%.
In comparison to its peers, CVS Health Corporation has a P/E ratio of 15.0, while Walgreens Boots Alliance shows a P/S ratio of 0.9. These comparisons indicate that MedAvail is trading at a discount relative to its industry peers. Additionally, MedAvail's recent stock performance has outpaced the Sensex, further supporting the case for its undervaluation.